This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study to Determine the Effectiveness of Escalating Doses of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: January 28, 2010
Last updated: October 22, 2012
Last verified: October 2012
This is an exploratory study. The purpose of the study is to determine whether escalating doses of RAD001 (everolimus) is safe and effective in patients with Lymphangioleiomyomatosis

Condition Intervention Phase
Lymphangioleiomyomatosis Drug: Everolimus Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Exploratory, Open Label, Non-randomized, Within-patient Multiple Dose-escalation Safety, Tolerability, PK and Efficacy Trial of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

Resource links provided by NLM:

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Assess safety, pharmacokinetics (PK) and pharmacodynamics (PD), Measure: Safety (vital signs, ECGs, safety labs, AEs), PK (concentration of everolimus), PD (serum VEGF-D) [ Time Frame: 26 weeks ]

Secondary Outcome Measures:
  • Clinical efficacy of everolimus Measure: improvement in pulmonary function (FVC) [ Time Frame: 26 weeks ]
  • Clinical efficacy of everolimus Measure: improvement in other measures of pulmonary function (FEV-1, lung volumes (TLC, TGV, RV), DLCO) [ Time Frame: 26 weeks ]
  • Clinical efficacy of everolimus Measure: improvement in exercise capacity (6-minute walk test), and change in O2 saturation (with supplemental oxygen unchanged) [ Time Frame: 26 weeks ]

Enrollment: 22
Study Start Date: December 2009
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: RAD001 2.5mg Drug: Everolimus
Experimental: RAD001 5mg Drug: Everolimus
Experimental: RAD001 10mg Drug: Everolimus


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female aged >/= 18 years with a diagnosis of LAM
  • Pulmonary function abnormalities as follows:
  • FEV1 of ≤ 80% of the predicted value following administration of a standard dose of a short acting β2-agonist (*200 µg Salbutamol, measured between 10 and 15 minutes of inhalation) OR
  • FEV1 < 90% of the predicted value of bronchodilator following administration of a standard dose of a short acting β2-agonist (*200 µg Salbutamol, measured between 10 and 15 minutes of inhalation) and DLco (uncorrected) <80% predicted.
  • Female patients including those of childbearing potential will be included in this study.
  • Negative pregnancy test at screening and baseline

Exclusion Criteria:

  • FEV1<50% of predicted post-bronchodilator.
  • Change in FVC (ml) > ± 15% of screening value at baseline visit (not less than 14d after screening visit).
  • Use of any medicine containing estrogen in the 4 months prior to the screening visit and for the duration of the study
  • Significant hematologic, renal, hepatic laboratory abnormality or amylase > 1.5x the upper limit of the normal range at the screening or baseline visits
  • Fasting blood glucose > 126mg/dl or random blood glucose >200mg/dl at screening and/or baseline
  • Recent surgery (involving entry into a body cavity or requiring sutures) within 2 months of the screening visit or any evidence of unhealed surgical wound.
  • Uncontrolled hyperlipidemia (defined as persistent elevation of total cholesterol or triglycerides >6.5nM/L) or a history of clinical atherosclerotic disease including heart attack, angina, peripheral vascular disease or stroke.
  • Previous organ transplantation
  • Inability to give informed consent
  • Inability to perform pulmonary function or 6 minute walk tests and imaging assessments

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01059318

United States, Massachusetts
Center for LAM Research and Clinical Care
Boston, Massachusetts, United States, 02115
United States, Ohio
University of Cincinnati, Department of Internal Medicine, Pulmonary, Critical Care & Sleep Medicine,
Cincinnati, Ohio, United States, 45267
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Grosshansdorf, Germany
Novartis Investigative Site
Leipzig, Germany
Novartis Investigative Site
Milan, Italy
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Novartis Pharmaceuticals
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Novartis Pharmaceuticals Identifier: NCT01059318     History of Changes
Other Study ID Numbers: CRAD001X2201
Study First Received: January 28, 2010
Last Updated: October 22, 2012

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
High Resolution CT scan,
chest x-ray,
6 minute walk test,
pulse oximetry,
renal MRI,

Additional relevant MeSH terms:
Lymphatic Vessel Tumors
Neoplasms by Histologic Type
Perivascular Epithelioid Cell Neoplasms
Neoplasms, Connective and Soft Tissue
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents processed this record on September 21, 2017